Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 clinical study of Sarconeos

Next Previous
Trial Profile

Phase 3 clinical study of Sarconeos

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarconeos (Primary)
  • Indications Sarcopenia
  • Focus Therapeutic Use
  • Acronyms SARA-32

Most Recent Events

  • 11 Feb 2025 According to a Biophytis media release, company plans to launch phase 3 of its SARA clinical program in the coming months.
  • 19 Jun 2023 According to a Biophytis media release, the company plans to initiate this study in the second half of 2023.
  • 18 Apr 2023 According to a Biophytis media release, Following the first Type C meeting with the FDA in January 2022, a scientific advice meeting was held with the EMA to discuss the Phase 3 protocol, targeting a similar population and endpoints as the Phase 2 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top